Small Molecules, Big Impact: Advancing Obesity Drug Discovery

Explore cutting-edge insights into small molecule innovations driving obesity and weight loss treatments. As obesity remains a complex and challenging therapeutic area, advances in small molecule drug discovery offer unparalleled promise—exemplified by breakthroughs like Eli Lilly’s oral GLP-1 receptor agonist, Orforglipron.

This poster outlines:

• The transformative potential of small molecules for CNS-targeted weight management therapies.
• Strategies to overcome drug discovery challenges, including polypharmacology, membrane-bound targets, and complex PK/DDI profiles.
• The critical advantage of integrated, co-located interdisciplinary teams (uniting pharmacologists, medicinal chemists, and DMPK experts) to accelerate informed decision-making and compound optimization.

Gain exclusive insights and accelerate your research!